Expanding the druggable proteome strategies and innovations in targeted protein degradation
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Protein Degradation and Inhibitors · Click Chemistry and Applications · Histone Deacetylase Inhibitors Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Targeted protein degradation: from mechanisms to clinic10.1038/s41580-024-00729-9 ↗
2. Molecular glue-mediated targeted protein degradation: A novel strategy in small-molecule drug development10.1016/j.isci.2024.110712 ↗
3. Mechanisms of disease progression and resistance to tyrosine kinase inhibitor therapy in chronic myeloid leukemia: an update10.3390/ijms20246141 ↗
4. Large-scale chemoproteomics expedites ligand discovery and predicts ligand behavior in cells
5. Small-molecule probes from bench to bedside: advancing molecular analysis of drug–target interactions toward precision medicine10.1039/D3CS00056G ↗
6. Proximity-based modalities for biology and medicine10.1021/acscentsci.3c00395 ↗
7. Selectivity through targeted protein degradation (TPD) miniperspective10.1021/acs.jmedchem.2c00397 ↗
8. Proteolysis-targeting drug delivery system (ProDDS): integrating targeted protein degradation concepts into formulation design10.1039/D4CS00411F ↗
9. Targeted protein degradation directly engaging lysosomes or proteasomes10.1039/D3CS00344B ↗
10. Key Mechanisms in Lysosome Stability, Degradation and Repair10.1080/10985549.2025.2494762 ↗
11. Targeted protein degradation: mechanisms, strategies and application10.1038/s41392-022-00966-4 ↗
12. Protein-Based Degraders: From Chemical Biology Tools to Neo-Therapeutics10.1021/acs.chemrev.4c00595 ↗
13. Targeted protein degradation for cancer therapy10.1038/s41568-025-00817-8 ↗
14. Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins10.7150/thno.62686 ↗
15. Advancing Proteolysis Targeting Chimera (PROTAC) Nanotechnology in Protein Homeostasis Reprograming for Disease Treatment10.1021/acsnano.4c09800 ↗
16. Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation10.1073/pnas.141230798 ↗
17. Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics10.1016/j.bmcl.2008.07.114 ↗
18. PROTAC Delivery Strategies for Overcoming Physicochemical Properties and Physiological Barriers in Targeted Protein Degradation10.3390/pharmaceutics17040501 ↗
19. PROTAC: an effective targeted protein degradation strategy for cancer therapy10.3389/fphar.2021.692574 ↗
20. An overview of PROTACs: a promising drug discovery paradigm10.1186/s43556-022-00112-0 ↗
21. Targeted protein degradation: advances, challenges, and prospects for computational methods10.1021/acs.jcim.3c00603 ↗
22. E3 ligase ligand optimization of Clinical PROTACs10.3389/fchem.2023.1098331 ↗
23. Park, Revolutionizing drug targeting strategies: integrating artificial intelligence and structure-based methods in PROTAC development10.3390/ph16121649 ↗
24. Mechanisms and regulation of substrate degradation by the 26S proteasome10.1038/s41580-024-00778-0 ↗
25. M. Słowianek, Cereblon-recruiting PROTACs: Will new drugs have to face old challenges?10.3390/pharmaceutics15030812 ↗
26. DCAF11 supports targeted protein degradation by electrophilic proteolysis-targeting chimeras10.1021/jacs.1c00990 ↗
27. Systematic identification of cancer cell vulnerabilities to natural killer cell-mediated immune surveillance10.7554/eLife.47362 ↗
28. Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF1510.1126/science.aal3755 ↗
29. Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF1610.1038/s41589-019-0279-5 ↗
30. A nimbolide-based kinase degrader preferentially degrades oncogenic BCR-ABL10.1021/acschembio.0c00348 ↗
31. Target and tissue selectivity of PROTAC degraders10.1039/D2CS00200K ↗
32. The potential of proteolytic chimeras as pharmacological tools and therapeutic agents10.3390/molecules25245956 ↗
33. Impact of linker length on the activity of PROTACs10.1039/C0MB00074D ↗
34. E3 ligase ligand chemistries: from building blocks to protein degraders10.1039/D2CS00148A ↗
35. A patent review of von Hippel-Lindau (VHL)-recruiting chemical matter: E3 ligase ligands for PROTACs and targeted protein degradation (2019–present)10.1080/13543776.2024.2446232 ↗
36. A novel rational PROTACs design and validation via AI-driven drug design approach10.1021/acsomega.3c10183 ↗
37. Rational Proteolysis Targeting Chimera Design Driven by Molecular Modeling and Machine Learning10.1002/wcms.70013 ↗
38. Advancing targeted protein degradation via multiomics profiling and artificial intelligence10.1021/jacs.2c11098 ↗
39. E3Docker: a docking server for potential E3 binder discovery10.1093/nar/gkaf391 ↗
40. DiffPROTACs is a deep learning-based generator for proteolysis targeting chimeras10.1093/bib/bbae358 ↗
41. DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs10.1038/s41467-022-34807-3 ↗
42. Accelerated rational PROTAC design via deep learning and molecular simulations10.1038/s42256-022-00527-y ↗
43. PROTAC beyond cancer-exploring the new therapeutic potential of proteolysis targeting chimeras10.2174/0115680266309968240621072550 ↗
44. Proteolysis targeting chimeras (PROTACs) come of age: entering the third decade of targeted protein degradation10.1039/D1CB00011J ↗
45. Proteolysis targeting chimeras (PROTACs): a perspective on integral membrane protein degradation10.1021/acsptsci.2c00142 ↗
46. Discovery of a potent HMG-CoA reductase degrader that eliminates statin-induced reductase accumulation and lowers cholesterol10.1038/s41467-018-07590-3 ↗
47. Induced protein degradation: an emerging drug discovery paradigm10.1038/nrd.2016.211 ↗
48. Protein degraders enter the clinic—a new approach to cancer therapy10.1038/s41571-023-00736-3 ↗
49. Chemistries of bifunctional PROTAC degraders10.1039/D2CS00220E ↗
50. Genetic compensation induced by deleterious mutations but not gene knockdowns10.1038/nature14580 ↗
51. The peptide PROTAC modality: a novel strategy for targeted protein ubiquitination10.7150/thno.46985 ↗
52. PHOTACs enable optical control of protein degradation10.1126/sciadv.aay5064 ↗
53. Light-induced control of protein destruction by opto-PROTAC
54. Sulfatase-induced in situ formulation of antineoplastic supra-PROTACs10.1021/jacs.4c00826 ↗
55. Glutathione-responsive PROTAC for targeted degradation of ERα in breast cancer cells10.1016/j.bmc.2023.117526 ↗
56. Development of hypoxia-activated PROTAC exerting a more potent effect in tumor hypoxia than in normoxia10.1039/D1CC05715D ↗
57. Proteolysis-targeting chimeras (PROTACs) in cancer therapy10.1186/s12943-021-01434-3 ↗
58. S. Lim, R. Khoo, K.M. Peh, J. Teo, S.C. Chang, S. Ng, G.L. Beilhartz, R.A. Melnyk, C.W. Johannes, C.J. Brown, bioPROTACs as versatile modulators of intracellular therapeutic targets including proliferating cell nuclear antigen (PCNA), Proc. Nat. Acad. Sci. 2020; 117: 5791-5800.10.1073/pnas.1920251117 ↗
59. Lipid-mediated intracellular delivery of recombinant bioPROTACs for the rapid degradation of undruggable proteins10.1038/s41467-024-50235-x ↗
60. Antibody conjugation of a chimeric BET degrader enables in vivo activity10.1002/cmdc.201900497 ↗
61. Roadmap for optimizing and broadening antibody-based PROTACs for degradation of cell surface proteins10.1021/acschembio.2c00185 ↗
62. From conception to development: investigating PROTACs features for improved cell permeability and successful protein degradation10.3389/fchem.2021.672267 ↗
63. Protein degradation by in-cell self-assembly of proteolysis targeting chimeras10.1021/acscentsci.6b00280 ↗
64. ClickRNA-PROTAC for tumor-selective protein degradation and targeted cancer therapy10.1021/jacs.4c06402 ↗
65. Molecular glues for protein-protein interactions: Progressing toward a new dream10.1016/j.chembiol.2024.04.002 ↗
66. Ultrasmall metal alloy nanozymes mimicking neutrophil enzymatic cascades for tumor catalytic therapy10.1038/s41467-024-45668-3 ↗
67. Development and therapeutic potential of GSPT1 molecular glue degraders: A medicinal chemistry perspective10.1002/med.22024 ↗
68. Immunophilin-sensitive protein phosphatase action in cell signaling pathways10.1016/0092-8674(92)90158-9 ↗
69. Molecular glues: the adhesive connecting targeted protein degradation to the clinic10.1021/acs.biochem.2c00245 ↗
70. A ligand-reversible dimerization system for controlling protein–protein interactions10.1073/pnas.100101997 ↗
71. Hierarchical phosphorylation of the translation inhibitor 4E-BP110.1101/gad.912401 ↗
72. Mechanism of action of the immunosuppressant rapamycin10.1016/0024-3205(95)02233-3 ↗
73. Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders10.1039/D2CS00116K ↗
74. A Dual-Target and Dual-Mechanism Design Strategy by Combining Inhibition and Degradation Together10.1021/jacs.4c11930 ↗
75. Molecular glues and induced proximity: An evolution of tools and discovery10.1016/j.chembiol.2024.04.001 ↗
76. Rational chemical design of molecular glue degraders10.1021/acscentsci.2c01317 ↗
77. DCAF16-Based covalent handle for the rational design of monovalent degraders10.1021/acscentsci.4c00286 ↗
78. Template-assisted covalent modification underlies activity of covalent molecular glues10.1038/s41589-024-01668-4 ↗
79. Molecular glues to stabilise protein–protein interactions10.1016/j.cbpa.2022.102169 ↗
80. Chasing molecular glue degraders: screening approaches10.1039/D2CS00197G ↗
81. Template-assisted covalent modification underlies activity of covalent molecular glues10.1038/s41589-024-01668-4 ↗
82. Advances in Targeting Drug Biological Carriers for Enhancing Tumor Therapy Efficacy10.1002/mabi.202300178 ↗
83. Thomas, Nanoparticles: taking a unique position in medicine10.3390/nano13030574 ↗
84. Review on nanoparticles and nanostructured materials: Bioimaging, biosensing, drug delivery, tissue engineering, antimicrobial, and agro-food applications10.3390/nano12030457 ↗
85. Targeted degradation of anaplastic lymphoma kinase by gold nanoparticle-based multi-headed proteolysis targeting chimeras10.1016/j.colsurfb.2020.110795 ↗
86. Targeted protein degradation via cellular trafficking of nanoparticles10.1038/s41565-024-01801-3 ↗
87. Nanoreceptors promote mutant p53 protein degradation by mimicking selective autophagy receptors10.1038/s41565-023-01562-5 ↗
88. Semiconducting polymer nano-PROTACs for activatable photo-immunometabolic cancer therapy10.1038/s41467-021-23194-w ↗
89. Nanoparticle-mediated cellular response is size-dependent10.1038/nnano.2008.30 ↗
90. Proteostasis and its role in disease development10.1007/s12013-024-01581-6 ↗
91. The Hsp70–Hsp90 chaperone cascade in protein folding10.1016/j.tcb.2018.10.004 ↗
92. Chaperone-mediated protein degradation (CHAMP): a novel technology for tumor-targeted protein degradation10.1158/1538-7445.AM2021-971 ↗
93. Advances in the structures, mechanisms and targeting of molecular chaperones10.1038/s41392-025-02166-2 ↗
94. A tough, antibacterial and antioxidant hydrogel dressing accelerates wound healing and suppresses hypertrophic scar formation in infected wounds
95. Lysosome-targeting chimaeras for degradation of extracellular proteins10.1038/s41586-020-2545-9 ↗
96. LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation10.1038/s41589-021-00770-1 ↗
97. Lysosome targeting chimaeras for Glut1-facilitated targeted protein degradation10.1021/jacs.4c02463 ↗
98. Aptamer-LYTACs for targeted degradation of extracellular and membrane proteins
99. Regulation of membrane protein structure and function by their lipid nano-environment10.1038/s41580-022-00524-4 ↗
100. Transferrin receptor targeting chimeras for membrane protein degradation10.1038/s41586-024-07947-3 ↗